Clinical Trial

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2023 (before its estimated November 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after hepatectomy.
Trial Details
NCT Number NCT06089382
Lead Sponsor Tongji Hospital
Conditions Hepatocellular Carcinoma
Enrollment 104 participants
Start Date 2023-11-01
Primary Completion 2024-11-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2023-10-18